See What HealthDay Can Do For You
Contact Us

High Costs for False-Positive Mammograms, Overdiagnosis

National expenditure estimated at $4 billion/year for false-positive mammograms, breast CA overdiagnosis

THURSDAY, April 9, 2015 (HealthDay News) -- Mammography screening is associated with considerable costs linked to false-positive mammograms and breast cancer overdiagnosis, with national expenditure estimated at $4 billion annually, according to a study published in the April issue of Health Affairs.

Mei-Sing Ong, Ph.D., from Boston Children's Hospital, and Kenneth D. Mandl, M.D., M.P.H., from Harvard Medical School in Boston, examined the costs due to false-positive mammograms and breast cancer overdiagnosis among women aged 40 to 59 years. Expenditure data were extracted from a major U.S. health care insurance plan for 702,154 women in the years 2011 to 2013.

The researchers found that in the 12 months following diagnosis, the average expenditures were $852, $51,837, and $12,369, respectively, for each false-positive mammogram, invasive breast cancer, and ductal carcinoma in situ. The national cost was estimated at $4 billion per year.

"The costs associated with false-positive mammograms and breast cancer overdiagnoses appear to be much higher than previously documented," the authors write. "Screening has the potential to save lives. However, the economic impact of false-positive mammography results and breast cancer overdiagnoses must be considered in the debate about the appropriate populations for screening."

Full Text (subscription or payment may be required)

Physician's Briefing